【Youth Daily】 Coimune, a joint venture between SCM Life Science and Genexine in the US, announced on the 7th that it has won an order for CDMO from Immunomic Therapeutics, a US biotechnology company.
Following the development of immune cell therapy, the company explained that it is expanding its business to CDMO, which has recently become a’hot trend’ in the bio industry.
CDMO (Contract Development and Manufacturing Organization) is a term in which’development’ is added to CMO, which means simple bio-consignment production. Through the CDMO business, bio companies can cooperate with various global companies and cultivate their capabilities for the development of new drugs, which is currently becoming a key trend in the bio field.
Under this contract, Coimune will be in charge of the development and production of’ITI-1020′, an mRNA-based immune anticancer drug targeting immunogenic glioblastoma. Coimune has secured not only the milestone related to the cGMP development of’ITI-1020′, but also the condition of receiving a portion of the sales as royalties when commercialized.
Immunomic is an American bio company that is developing immune cell therapy based on the core technology of the immune vaccine platform’UNITE’. Transferred.
The UNITE platform can enhance the function of human immune cells in a way that works to target specific antigens intensively. Immunomic is developing an immune cell therapy pipeline that can be applied to cancer, allergies, and other infectious diseases using the platform.
Ahead of the signing of the CDMO contract, Immunomic is known to have highly evaluated Coimune’s cGMP manufacturing capabilities.
cGMP is the quality control standard for manufacturing excellent pharmaceuticals, and in order to enter the US market, the world’s largest pharmaceutical and bio market, the standard must be met. Coimune has cGMP manufacturing facilities including 10 ISO-7 rooms and 4 QC laboratories on approximately 560 pyeong of land in North Carolina, USA.
Coimune’s cGMP process that meets global standards is expected to become a good guideline for domestic bio companies preparing for CDMO business.
Coimune is a bio-venture company that develops various anti-cancer pipelines based on CAR-CIK immune cells. Currently, it is securing pipelines for dendritic cell-based immune cell therapy (CMN-001), which is undergoing clinical 2b in the US, and acute lymphocytic leukemia therapy (CARCIK-CD19), which is undergoing phase 1 clinical trials in Europe.
“We are pleased to be able to cooperate with Immunomics, which has new and emerging professional technologies,” said Charles Nicolette, CEO of Coimune. I look forward to being able to do it.”
【Youth Daily = Reporter Ahn Sang-jun】